Vol. 2, Issue 1, Part A (2020)

The utilization of 3D printing in the production of pharmaceuticals, known as Zip-Dose technology, is a significant development in the pharmaceutical industry. This technology enables the production of personalized medication, improving medication adherence and overall patient compliance. However, the introduction of this technology poses complex regulatory challenges that must be addressed. This article aims to explore the regulatory implications of 3D printing Zip-Dose technology in the pharmaceutical industry. With the advancement of 3D printing technology, the potential for personalized medicine and on-demand drug manufacturing has increased significantly. Zip-Dose technology, a specific application of 3D printing, enables the production of individualized dosage forms with precise drug dosing and release profiles. This article discusses the regulatory considerations associated with 3D printing Zip-Dose technology, including quality control, validation, intellectual property, and regulatory approval processes. Furthermore, it examines the challenges and opportunities posed by this emerging technology, along with the potential impact on healthcare delivery and patient outcomes. The analysis presented in this article emphasizes the importance of developing appropriate regulatory frameworks to ensure the safe and effective implementation of 3D printing Zip-Dose technology in the pharmaceutical industry.